Six infections versus zero is something, but the sample size is still not enough
Six months into the largest vaccination effort in modern history, Pfizer and BioNTech have offered the world a measured reassurance: their messenger RNA vaccine holds firm at 91.3% efficacy, a modest retreat from early promise but a confirmation that science can keep pace with a virus in motion. More striking still, in a small cohort in South Africa — ground zero for one of the most worrying variants — not a single vaccinated participant contracted the B.1.351 strain, while six placebo recipients did. The data does not close the chapter on uncertainty, but it marks the first human evidence that the tools humanity has built may be equal to the challenge of a shifting adversary.
- The South African variant B.1.351 had alarmed scientists worldwide, with lab studies suggesting existing vaccines might struggle against it — and it had already spread to more than 25 U.S. states.
- Six months of real-world follow-up data revealed a slight but notable dip in efficacy, from 95% to 91.3%, raising questions about how protection holds over time against an evolving virus.
- In a critical South African trial subset, zero vaccinated participants were infected with B.1.351 versus six in the placebo group — the first human evidence of mRNA vaccine effectiveness against the variant, though experts urge caution given the small sample size.
- Pfizer's CEO announced the extended data now supports a push for full FDA approval, moving beyond emergency authorization toward a more permanent regulatory footing.
- Both companies are already preparing booster shots tailored to emerging variants, and new trials in adolescents aged 12 to 15 signal the next frontier in expanding vaccine access.
Pfizer and BioNTech released updated trial results showing their COVID-19 vaccine holds at 91.3% efficacy across six months of follow-up in over 12,000 fully vaccinated participants. The figure marks a modest decline from the initial 95% reported in November, but independent experts and the companies alike framed it as strong evidence the vaccine remains a powerful tool against a virus that continues to mutate.
The most closely watched finding involved the South African variant, B.1.351 — a strain that had already reached more than 25 U.S. states and raised fears that existing vaccines might be outpaced. In a subset of roughly 800 South African trial volunteers, nine COVID-19 cases emerged during the study period. Every single one occurred in the placebo group. Six of those nine involved B.1.351 specifically. Among vaccinated participants, there were zero infections with the variant — the first human clinical evidence that an mRNA vaccine could hold the line against it.
Virologist Shane Crotty of the La Jolla Institute called the results "a big deal," while cautioning that the sample size was too small for definitive conclusions. The vaccine also showed 95.3% efficacy against severe disease as defined by the FDA, with no serious safety concerns emerging through six months of monitoring.
Pfizer's chief executive Albert Bourla said the extended data positioned the company to seek full FDA approval rather than continuing under emergency authorization. BioNTech's Ugur Sahin described the findings as the first clinical proof that a vaccine could protect against currently circulating variants, and framed vaccination as a viable path to global herd immunity.
Both companies acknowledged that booster shots targeting new variants would likely become necessary, and said preparations were already underway. Trials in adolescents aged 12 to 15 have also begun, setting the stage for an expanded authorized age range. As immunologist Danny Altmann of Imperial College London observed, the question is no longer whether the vaccine works — it is how long that protection endures, and what a sustainable long-term response will look like.
Pfizer and BioNTech released updated trial results on Thursday showing their COVID-19 vaccine maintains 91.3% efficacy when measured across six months of follow-up in over 12,000 fully vaccinated participants. The figure represents a modest decline from the initial 95% efficacy announced in November based on a 44,000-person trial, yet the companies and independent experts framed the result as reassuring evidence that the vaccine remains a formidable weapon against a virus that continues to evolve.
What made these numbers particularly significant was what they revealed about protection against the South African variant, B.1.351—a strain that has alarmed public health officials worldwide. In a subset of roughly 800 study volunteers in South Africa, where this variant circulates widely, the vaccine showed early clinical evidence of effectiveness. Among that group, nine COVID-19 cases emerged during the trial period. All nine occurred in people who received the placebo. Of those nine, six involved infection with the South African variant specifically. Zero infections with B.1.351 occurred among vaccinated participants in this cohort.
The stakes surrounding variant protection had grown urgent. Lab studies suggested the Pfizer vaccine was somewhat less potent against B.1.351 than against the original virus, yet still offered meaningful defense. The South African variant had already been detected in more than 25 U.S. states and jurisdictions. A separate Brazilian variant raised similar concerns. Experts worried these strains might partially evade the protection offered by existing vaccines. The Thursday data provided the first real-world human evidence that the Pfizer shot could still work against B.1.351—a critical question that had remained unanswered until then.
Shane Crotty, a virologist at the La Jolla Institute for Immunology, called the results "a big deal," noting they offered the first human data on how messenger RNA vaccines would perform against the South African variant. He cautioned, however, that the sample size remained too small to draw definitive conclusions about the degree of protection. "Six infections versus zero is something," he wrote, but the numbers needed to be understood as preliminary.
The vaccine also demonstrated 95.3% efficacy against severe disease as defined by the FDA. Safety monitoring through six months after the second dose revealed no serious concerns. The trial had tracked more than 900 confirmed COVID-19 cases overall, the vast majority occurring among placebo recipients.
Albert Bourla, Pfizer's chief executive, said the extended safety and efficacy data positioned the company to pursue full FDA approval rather than continuing under emergency authorization. BioNTech's chief executive, Ugur Sahin, framed the results as evidence that vaccination could achieve herd immunity and end the pandemic globally, emphasizing that these were "the first clinical results that a vaccine can effectively protect against currently circulating variants."
Both companies acknowledged that new variants would likely emerge and that booster shots tailored to address them might become necessary. BioNTech said it was already preparing to upgrade its vaccine formula when needed. The companies also announced they had begun trials in adolescents aged 12 to 15, setting the stage for regulatory applications to expand the vaccine's authorized age range in the United States and Europe.
Danny Altmann, an immunology professor at Imperial College London who was not involved in the trial, offered measured perspective: the updated results reinforced that "we have some really potent vaccines." The question now was not whether the vaccine worked, but how long that protection would last and whether periodic boosters would become part of the long-term pandemic response.
Notable Quotes
These data reinforce our view that we have some really potent vaccines.— Danny Altmann, immunology professor, Imperial College London
The first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population.— Ugur Sahin, chief executive, BioNTech
The Hearth Conversation Another angle on the story
The efficacy dropped from 95% to 91%. Does that mean the vaccine is getting weaker?
Not exactly. The original 95% was measured over a shorter window with fresher data. This 91.3% comes from following the same people for six months—it's the same vaccine, just watched longer. The slight decline is normal; immunity doesn't stay frozen at peak levels.
But what about the South African variant? That's the real worry, isn't it?
Yes. Lab tests had suggested the vaccine might struggle against B.1.351. What Thursday's data showed for the first time was actual people in South Africa getting vaccinated and not getting sick with that variant. Nine cases in the trial group—all in the placebo arm. That's real-world evidence, not just test tubes.
Nine cases is a small number though. Can you really trust that?
That's the honest tension. The virologist I mentioned said it's meaningful but not conclusive. You need bigger numbers to be certain. But it's the first human data we had, so even preliminary evidence mattered.
What happens next? Do people need boosters?
The companies are already preparing for that possibility. They're designing boosters that could target new variants if they emerge. But that's future planning. Right now, the data says the current vaccine still works against the variants we're seeing.
Why does Pfizer want full FDA approval now instead of staying under emergency use?
Extended safety data. They've now tracked over 12,000 people for six months with no serious safety signals. That's the kind of evidence regulators want for permanent approval. It's a sign of confidence in the vaccine's long-term profile.
And they're testing it in teenagers?
Yes. If those trials go well, they can ask the FDA to authorize it for 12- to 15-year-olds. That expands who can be protected and moves closer to vaccinating the whole population.